Ustekinumab Injection Suppliers & Bulk Manufacturers

Available Forms: SQ and IV injection

Available Strengths: SQ:: 45 mg, 90 mg; IV: 130 mg/vial

Reference Brands: Stelara(US)

Category: Immune Disorder

Ustekinumab inhibits interleukins IL-12 and IL-23, key cytokines involved in inflammatory and immune responses. It reduces inflammation, alleviates symptoms of psoriasis, psoriatic arthritis, and Crohn’s disease, and improves quality of life. Benefits include targeted action, long-term disease control, and a favorable safety profile in autoimmune therapy.

Product Description: Ustekinumab injection, marketed as Stelara, is approved in the US by the FDA and in the EU via EMA for Crohn’s disease, psoriatic arthritis, and psoriasis. Regulatory approval requires comprehensive dossiers including clinical trial data, manufacturing details, safety, efficacy, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and quality data, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market entry strategies, visit PharmaTradz. Ensuring thorough regional compliance is essential for the safe, effective, and timely approval of ustekinumab injectable products worldwide, supporting optimal patient outcomes in autoimmune disease management.